查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
基因組生物標誌物的全球市場-2022-2029
市場調查報告書
商品編碼
1129276

基因組生物標誌物的全球市場-2022-2029

Global Genomic Biomarker Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

政府當局對醫療保健行業的投資不斷增長，預計將推動市場增長。

根據醫療保險和醫療補助服務中心 (CMS) 的估計，從 2018 年到 2027 年，美國國家醫療保健支出將以年均 5.5% 的速度增長，屆時將達到約 6 萬億美元。預計。此外，2020 年 5 月，開發分子診斷技術的德國 Qiagen 公司宣布引入最先進的技術，用於各種類型的癌症的基因組分析。最先進的 QIAseq pan-cancer multimodal panel 發現並富集了 600 多種 DNA 和 RNA 生物標誌物，用於評估腫瘤突變負荷和微衛星不穩定性狀態，只需輸入一個樣本即可。因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

基因組生物標誌物的高成本、嚴格的政府法規以及僅基於遺傳生物標誌物的診斷方法的不可靠性。這些是預計在預測期內阻礙市場的一些因素。

行業分析

基因組生物標誌物市場提供基於各種行業因素的市場深入分析，包括供應鏈分析、定價分析等。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。 SARS-CoV-2具有冠狀病毒家族的共同特性，結構特徵和進入機制已經闡明。另一方面，快速誘變會導致形成具有不同繁殖率和傳染性的新菌株，從而影響疾病的性質和嚴重程度。 COVID-19 的強度、結果和易感性都被認為受宿主相關因素的影響。生物信息學可用於預測刺突蛋白突變對該菌株感染細胞和粘附 ACE2 受體能力的影響。

此外，SARS-CoV-2 靶向多種轉錄因子和腫瘤抑制基因，並可能影響許多宿主基因的表達和細胞信號傳導。它還可以利用內源性 miRNA 及其病毒 RNA 來抑制宿主細胞中的 RNA 表達。某些人類 miRNA 已被證明與病毒 RNA 的各種編碼和非編碼區相關以形成雙鏈體。此外，參與病毒進入和復制、分子損傷反應和炎症途徑的人類基因多態性可能會影響疾病的預後和病程。基因本體分析表明，這些多態基因編碼的蛋白質與防禦反應的控制密切相關。因此，病毒宿主相關的遺傳和表觀遺傳生物標誌物可能有助於預測疾病進展和治療效果。

另一方面，大流行會破壞供應鍊和流程。許多公司將轉移到其他地區以確保產品可用性並保護其供應鏈。因此，從上述描述來看，市場受到了影響，但預計隨著經濟活動的恢復，市場將急劇回升。

此報告提供對大約 45 多個市場數據表、40 多個數字和 200 頁的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 政府當局對醫療保健行業的投資不斷增加，預計將推動市場增長。
    • 限制因素
      • 基因組生物標誌物的高成本預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格波動
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 預測性生物標誌物
  • 預後生物標誌物

第 8 章通過驗證

  • 分析驗證
  • 臨床驗證
  • 臨床實用性
  • 其他

第 9 章適應症

  • 腫瘤學
  • 心血管疾病
  • 神經系統疾病
  • 腎病
  • 其他

第 10 章，最終用戶

  • 醫院
  • 診斷中心
  • 研究所
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 13 章公司簡介

  • Thermo Fisher Scientific
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Eurofins Scientific
  • Exact Sciences
  • Sema4
  • Creative Diagnostics
  • Centogene N.V.
  • Quanterix

第 14 章全球基因組生物標誌物市場-DataM

簡介目錄
Product Code: DMOT5830

Market Overview

Genomic Biomarker Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 15% during the forecast period (2022-2029).

Genomic biomarkers are signs that assess for clinical diagnosis based on gene expression, gene mutation, gene regulation, and other gene features. Neurological, oncological, and cardiovascular illnesses can all be detected using genomic biomarkers. Genomic biomarkers aid in the early diagnosis of disease, tracking disease progression and assessing the biological response to treatment or therapy. Genomic biomarkers can be utilized as a diagnostic indicator on their own or in conjunction with other biomarkers such as protein biomarkers. mRNA, miRNA, cell-free DNA, long coding RNA, and other genomic biomarkers are used in clinical diagnosis.

Market Dynamics

The growing investment by government authorities in the healthcare industry is expected to drive market growth.

The Centers for Medicare & Medicaid Services (CMS) estimates that national health spending in the United States increased at an average rate of 5.5 percent per year from 2018 to 2027 and is projected to reach around USD 6.0 trillion by that time. Moreover, in May 2020, Qiagen, a German company that develops molecular diagnostics technology, announced the introduction of cutting-edge technologies for genomic analysis in various cancer kinds. The cutting-edge QIAseq pan-cancer multimodal panel with just one sample input can discover and enrich more than 600 DNA and RNA biomarkers for evaluating tumor mutational load and microsatellite instability status. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs of the genomic biomarkers, stringent government restrictions, and diagnostic method based solely on genetic biomarkers is less reliable. These are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The genomic biomarker market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The structural characteristics and entrance mechanism of SARS-CoV-2 are clarified due to the shared characteristics of the coronavirus family. Rapid mutagenesis, on the other hand, causes the formation of novel strains that may have various rates of reproduction or infectiousness and may affect the nature and severity of the illness. The intensity and results of COVID-19 and the susceptibility to infection may all be influenced by host-related factors. The impact of spike protein mutations on the strain's ability to infect cells and attach to the ACE2 receptor can be predicted using bioinformatics.

Additionally, SARS-CoV-2 may target several transcription factors and tumor suppressor genes, impacting the expression of many host genes and cell signaling. By using endogenous miRNA and its viral RNA, the virus may also impede RNA expression in host cells. It is revealed that certain human miRNA may associate with various coding and non-coding regions of viral RNA to produce duplexes. Polymorphisms may also influence the prognosis and course of a disease in human genes involved in viral entry and replication, as well as in molecular damage response and inflammatory pathways. Proteins encoded by these polymorphic genes are highly related to the regulation of the defense response, according to a gene ontology analysis. Genetic and epigenetic biomarkers connected to the virus and host may therefore aid in predicting the progression of the disease and the effectiveness of treatment.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Predictive Biomarkers segment is expected to hold the largest market share in genomic biomarker market

The predictive biomarkers segment is expected to dominate in 2021. The segment benefits because predictive biomarkers are baseline or pretreatment data that reveal whether patients are more or least likely to benefit from a certain treatment. A predictive biomarker is frequently chosen as a companion predictive biomarker in developing a specific therapeutic medication. As a typical oncology example, a biomarker that detects overexpression of the growth factor protein Her-2, which transmits growth signals to breast cancer cells, maybe a predictive biomarker for the administration of trastuzumab (Herceptin). This drug inhibits the effects of Her-2 on breast cancer patients. Therefore, it has increased the demand for predictive biomarkers. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global genomic biomarker market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer and cardiovascular disease, advancements in the genomic biomarker, increasing adoption of genomic biomarkers in the early diagnosis of diseases, product launches by the key market players, and regulatory approvals in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of genomic biomarkers in the early diagnosis of diseases.

Moreover, Clinical genomics delivery in everyday healthcare has been completed under Color Genomics' US program, the company announced in January 2020 in collaboration with NorthShore University HealthSystem. Additionally, the business supported Sanford's Imagenetics genomes program, which will improve clinical judgment. This project is also to blame for the region's widespread use of genetic biomarkers. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the genomic biomarker market are Thermo Fisher Scientific,Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Exact Sciences, Sema4, Creative Diagnostics, Centogene N.V., Quanterix.

Bio-Rad Laboratories, Inc.:

Overview:

Bio-Rad Laboratories, Inc. is an American company that continues to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process, and medical diagnostic labs obtain faster results. Bio-Rad's life science products include instruments, software, consumables, reagents, and content for cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. Moreover, Bio-Rad's diagnostic products and systems use various technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products support diagnosing, monitoring, and treating diseases and other medical conditions.

Product Portfolio:

CFX Real-Time PCR Detection System: Powerful and flexible instruments with 2-5 color multiplexing to deliver sensitive, reliable detection of both single and multiplex real-time PCR reactions. High-throughput CFX Automation System can screen up to 84 plates in 24 hours.

The global genomic biomarker market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing investment by government authorities in the healthcare industry is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs of the genomic biomarkers are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Predictive Biomarkers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Prognostic Biomarkers

8. By Validation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 8.1.2. Market Attractiveness Index, By Validation Segment
  • 8.2. Analytical Validation*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinical Validation
  • 8.4. Clinical Utility
  • 8.5. Others

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication Segment
  • 9.2. Oncology*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cardiovascular Diseases
  • 9.4. Neurological Diseases
  • 9.5. Renal Disorders
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Research Laboratories
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Thermo Fisher Scientific*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bio-Rad Laboratories, Inc.
  • 13.3. Myriad Genetics, Inc.
  • 13.4. QIAGEN
  • 13.5. Eurofins Scientific
  • 13.6. Exact Sciences
  • 13.7. Sema4
  • 13.8. Creative Diagnostics
  • 13.9. Centogene N.V.
  • 13.10. Quanterix

LIST NOT EXHAUSTIVE

14. Global Genomic Biomarker Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us